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Here, we report a cell-intrinsic mechanism by which
oncogenic RAS promotes senescence while predis-
posing cells to senescence bypass by allowing
for secondary hits. We show that oncogenic RAS
inactivates the BRCA1 DNA repair complex by
dissociating BRCA1 from chromatin. This event
precedes senescence-associated cell cycle exit
and coincides with the accumulation of DNA
damage. Downregulation of BRIP1, a physiological
partner of BRCA1 in the DNA repair pathway, triggers
BRCA1 chromatin dissociation. Conversely, ectopic
BRIP1 rescues BRCA1 chromatin dissociation and
suppresses RAS-induced senescence and the DNA
damage response. Significantly, cells undergoing
senescence do not exhibit a BRCA1-dependent
DNA repair response when exposed to DNA damage.
Overall, our study provides a molecular basis by
which oncogenic RAS promotes senescence.
Because DNA damage has the potential to produce
additional ‘‘hits’’ that promote senescence bypass,
our findings may also suggest one way a small
minority of cells might bypass senescence and
contribute to cancer development.
INTRODUCTION
Activation of oncogenes (such as RAS) in primary mammalian
cells typically triggers a cascade of molecular and cellular
events, which ultimately culminates in a state of irreversible
cell growth arrest (Campisi, 2005). This process is termed
oncogene-induced senescence and is an important tumor
suppression mechanism in vivo (Campisi, 2005). Paradoxically,
the definition of an oncogene is a gene that actively promotes
tumorigenesis. The mechanism underlying this paradox remains
poorly understood.DevelopmentaSenescent cells display several hallmark morphological and
molecular characteristics. These cells are positive for senes-
cence-associated b-galactosidase (SA-b-gal) activity (Dimri
et al., 1995). In addition, chromatin in the nuclei of senescent
human cells often reorganizes to form specialized domains of
facultative heterochromatin called senescence-associated
heterochromatin foci (SAHF) (Braig et al., 2005; Narita et al.,
2003, 2006; Zhang et al., 2005, 2007a). SAHF contain markers
of heterochromatin, including di- and tri-methylated lysine 9
histone H3 (H3K9Me2/H3K9Me3), histone H2A variant mH2A,
and HMGA (Narita et al., 2003, 2006; Zhang et al., 2005). SAHF
formation contributes to senescence-induced cell cycle exit by
directly sequestering and silencing proliferation-promoting
genes (Narita et al., 2003; Zhang et al., 2007a).
Oncogene-induced senescence is often characterized by the
accumulation of DNA damage; in particular, DNA double-strand
breaks (DSBs) (Bartkova et al., 2006; Di Micco et al., 2006). For
example, oncogenic RAS mutants induce DNA damage by
triggering aberrant DNA replication (Di Micco et al., 2006).
However, it remains to be determined whether impaired DNA
repair contributes to the accumulation of DNA damage observed
during oncogene-induced senescence.
BRCA1 plays an important role in DNA DSB repair (Scully and
Livingston, 2000). Germline mutations in the BRCA1 gene
predispose women to breast and ovarian cancer (Scully and
Livingston, 2000), and inactivation of BRCA1 contributes to
cancer development by causing genomic instability (Turner
et al., 2004). BRCA1 interacts with various DNA damage repair
proteins through its two C terminus BRCA1 C-terminal (BRCT)
repeats. The BRCT repeats of BRCA1 recognize cognate part-
ners by binding to their phosphoserine residues (Manke et al.,
2003; Yu et al., 2003), and their binding partners include
BRCA1-interacting protein 1 (BRIP1), CtIP, and RAP80/Abraxas
(Wang et al., 2007; Yu et al., 1998, 2003). In addition, BRCA1
interacts with partner and localizer of BRCA2 (PALB2), which is
necessary for localization of BRCA2 to DNA DSBs (Xia et al.,
2006). Functional BRCA1 is required for localizing/sustaining
PALB2 at sites of DNA DSBs and error-free homologous recom-
bination repair (Livingston, 2009; Sy et al., 2009; Zhang et al.,
2009). A role for BRCA1 in senescence is implied by findings
from the BRCA1 exon 11 knockout mouse whose cells exhibitl Cell 21, 1077–1091, December 13, 2011 ª2011 Elsevier Inc. 1077
Figure 1. Oncogene-Induced Dissociation of BRCA1 from Chromatin Occurs prior to the Oncogene-Induced Cell Cycle Exit and Coincides
with the Accumulation of DNA Damage during Senescence
(A) IMR90 cells were infected with retrovirus-encoding control or oncogenic RAS to induce senescence. Drug-selected cells were stained with DAPI to visualize
SAHF and an anti-BRCA1 antibody at day 5. Arrows point to an example of BRCA1-excluded SAHF in senescent IMR90 cells.
(B) Same as (A) but examined for expression of BRCA1, b-actin, and histone H3 in soluble (cytoplasmic soluble fraction SN1 and nuclear soluble fraction SN2) and
chromatin fractions of control (C) or RAS (R)-infected IMR90 cells by western blot. Note that equal amounts of total proteins were loaded for total cell lysates, SN1,
SN2, and chromatin fractions.
(C) Same as (A). At days 1 and 6, control and RAS-infected cells were labeledwith BrdU for 1 hr (left) or stained with DAPI to visualize SAHF and antibodies against
mH2A and H3K9Me2 that form foci that colocalize with SAHF in senescent human cells (right).
(D and E) Time course of BrdU labeling (D) and formation of SAHF, mH2A, and H3K9Me2 foci (E) in control and RAS-infected IMR90 cells. Mean of three
independent experiments with SD.
(F) Same as (D) but examined for expression of BRCA1, gH2AX, and histone H3 in the chromatin fractions of control and RAS-infected cells at the indicated time
points by western blot.
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suggest that senescence and tumorigenesis pathways may
converge on BRCA1-associated DNA damage responses.
Here, we report a cell-intrinsic mechanism by which onco-
genic RAS promotes senescence but at the same time predis-
poses cells to secondary hits, which ultimately leads to senes-
cence bypass.
RESULTS
BRCA1 Becomes Dissociated from Chromatin during
Oncogenic RAS-Induced Senescence
Senescent cells are characterized by the accumulation of DNA
DSBs (Bartkova et al., 2006; Di Micco et al., 2006; Halazonetis
et al., 2008), and one of the critical players in DSB repair is
BRCA1 (Scully and Livingston, 2000). To test the hypothesis
that changes in BRCA1 function occur during oncogene-
induced senescence, we first examined changes in the subcel-
lular distribution of BRCA1 during RAS-induced senescence of
IMR90 primary human fibroblasts (see Figure S1A available on-
line). BRCA1 immunofluorescence (IF) staining was performed
in proliferating (control) and senescent IMR90 primary human
fibroblasts induced by RAS. Notably, BRCA1 was excluded
from SAHF in senescent cells (Figure 1A). In addition, similar
results were obtained using multiple anti-BRCA1 antibodies
(one rabbit polyclonal and two individual mouse monoclonal
antibodies) (data not shown). We next fractionated protein
from proliferating (control) and senescent IMR90 cells into
soluble and chromatin fractions (Me´ndez and Stillman, 2000;
Narita et al., 2006) and tested each for the presence of
BRCA1. Compared with control cells, BRCA1 levels were
dramatically decreased in the chromatin fractions of senescent
IMR90 cells (Figure 1B; Figure S1B).
We next sought to exclude the possibility that BRCA1
chromatin dissociation was caused by supra-physiological
levels of RAS. To do so, we titrated RAS expression in IMR90
cells to levels lower than those in the classic bladder cancer
cell line T24 that harbors an oncogenic RAS mutation (H-
RASG12V, the same RASmutant used in the current study) (Hurlin
et al., 1989) (Figure S1C). Importantly, we observed a decrease
in BRCA1 levels in the chromatin fractions of RAS-infected
IMR90 cells with lower RAS expression than the T24 cells (Fig-
ure S1C). Interestingly, BRCA1 levels in the chromatin fractions
of T24 cells were also notably lower when compared to IMR90
cells, albeit similar levels of total BRCA1 levels were observed
(Figure S1C). Together, our data show that the physiological
levels of oncogenic RAS observed in cancerous cells are suffi-
cient to dissociate BRCA1 from chromatin in primary cells.
Next, we asked whether BRCA1 chromatin dissociation is
unique to IMR90 cells induced to senesce by RAS. To answer(G and H) Same as (D) but stained for cyclin A expression (using a mouse anti-c
(I and J) At day 2, control and RAS-infected cells were labeled with BrdU for 1 h
details). Pre-extracted cells were stained with antibodies against BRCA1 and Brd
cells was quantified using MetaMorph software (J) (n = 30).
(K) Same as (D) but examined for cell cycle distribution by flow cytometry.
(L and M) Same as (D) but examined for expression of gH2AX (L) or 53BP1 (M) e
were examined for formation of gH2AX or 53BP1 foci. Mean of three independe
See also Figure S1.
Developmentathis question, primary WI38 and BJ human fibroblasts, which
both senesce after oncogenic RAS is expressed (Ye et al.,
2007; Zhang et al., 2005) (data not shown), were infected with
control or RAS-encoding retrovirus. Compared with controls,
BRCA1 levels were dramatically decreased in the chromatin
fractions of RAS-infected WI38 and BJ cells (Figure S1D). Taken
together, these data demonstrate that BRCA1 becomes dis-
sociated from chromatin during RAS-induced senescence.
BRCA1 Chromatin Dissociation Precedes the Cell Cycle
Exit during RAS-Induced Senescence
We next sought to determine whether BRCA1 chromatin disso-
ciation occurs early or late during RAS-induced senescence.
Toward this goal, we conducted a detailed time course analysis
of chromatin-associated BRCA1, senescence-associated cell
cycle exit (determined by BrdU incorporation or expression of
cyclin A or serine 10 phosphorylated histone H3 [pH3S10]),
and other markers of senescence (such as formation of SAHF,
mH2A foci, and H3K9Me2 foci) in control and RAS-infected
IMR90 cells (Figures 1C–1H). Strikingly, as early as day 1 (Fig-
ure S1A), BRCA1 was largely dissociated from chromatin (Fig-
ure 1F; Figure S1K), which is well before the senescence-
associated cell cycle exit and accumulation of markers of
senescence (Figures 1C–1H).
BRCA1 forms discrete nuclear foci during the S/G2 phases of
the cell cycle in normal cycling cells (Durant and Nickoloff,
2005; Scully et al., 1997a; Xu et al., 2001). Therefore, we sought
to determine whether RAS expression impairs BRCA1 foci
formation in cycling cells. Toward this goal, at day 2, control
and RAS-infected IMR90 cells were labeled with BrdU to iden-
tify S phase cells. We next pre-extracted soluble proteins from
control and RAS-infected cells and stained these cells with
antibodies against BRCA1 and BrdU. Indeed, the intensity of
BRCA1 foci in BrdU-positive cells was significantly weaker in
RAS-infected IMR90 cells compared with controls (p = 0.009)
(Figures 1I and 1J). This is not simply a consequence of DNA
damage because this did not occur in ionizing radiation
(IR)-treated cells (Figures S1E and S1F). Furthermore, control
and RAS-infected IMR90 cells were stained with antibodies
against BRCA1 and cyclin A, a marker of the S/G2 phases of
the cell cycle (Erlandsson et al., 2000; Sartori et al., 2007).
Consistently, BRCA1 foci were either negative or notably
weaker in cyclin A-positive RAS-infected cells compared with
controls (Figures S1G and S1H). Finally, FACS analysis re-
vealed that RAS-infected cells accumulated at the S and G2/
M phases of the cell cycle compared with controls at this stage
(day 2) (Figure 1K; Figures S1I and S1J). From these results,
we conclude that oncogene-induced dissociation of BRCA1
from chromatin precedes the oncogene-induced cell cycle
exit during senescence.yclin A antibody) (G) or pH3S10 (H) by IF at the indicated time points.
r, and soluble proteins were pre-extracted (see Experimental Procedures for
U. The intensity of BRCA1 staining in BrdU-positive control and RAS-infected
xpression by IF staining. A total of 200 cells from each of the indicated groups
nt experiments with SD.
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Accumulation of DNA Damage
We next asked whether BRCA1 chromatin dissociation plays
a role in the DNA damage accumulation observed during RAS-
induced senescence. Strikingly, accumulation of markers of
DNA damage, including formation of gH2AX and 53BP1 foci,
accumulation of gH2AX in chromatin fractions, and upregulation
of p53 displayed the identical kinetics as dissociation of BRCA1
from chromatin in RAS-infected IMR90 cells (Figures 1F, 1L, 1M;
Figures S1K–S1O). For example, as early as day 1, gH2AX
had already accumulated in chromatin fractions (Figure 1F; Fig-
ure S1K), gH2AX and 53BP1 foci were increased, and the p53
expression levels were upregulated in RAS-infected IMR90 cells
compared with controls (Figures 1L and 1M; Figures S1L–S1O).
We conclude that RAS expression results in concomitant
BRCA1 chromatin dissociation and DNA damage accumulation.
To determine whether BRCA1 chromatin dissociation is a
RAS-specific effect, IMR90 cells were infected with control,
RAS, BRAF, or myristylated AKT1 (myr-AKT1)-encoding retro-
virus. Ectopic expression of RAS, BRAF, and myr-AKT1 was
confirmed by western blot (data not shown). Notably, expression
of RAS, BRAF, and myr-AKT1 all induced expression of markers
of senescence in IMR90 cells (Figure S2A) (Krizhanovsky et al.,
2008; Michaloglou et al., 2005; Xue et al., 2007; Zhang et al.,
2005). Next, we examined BRCA1 protein levels in total cell
lysates and chromatin fractions of control, RAS, BRAF, and
myr-AKT1-infected IMR90 cells by western blot. Strikingly,
compared with controls, BRCA1 levels decreased dramatically
in the chromatin fractions of RAS and BRAF-infected IMR90
cells, but not in myr-AKT1-infected IMR90 cells (Figure 2A).
These results suggest that BRCA1 chromatin dissociation is
dependent upon specific oncogenic pathways and is not simply
a consequence of senescence.
We next sought to determine whether BRCA1 chromatin
dissociation coincides with DNA damage accumulation or is
associated with SAHF formation. Toward this goal, control,
RAS, BRAF, and myr-AKT1-infected IMR90 cells were stained
with DAPI to visualize SAHF and with an antibody to mH2A,
which is a component of SAHF (Zhang et al., 2005). Both RAS
and BRAF, but not myr-AKT1, induced formation of SAHF and
mH2A foci (Figure 2B). Additionally, compared with controls,
both RAS and BRAF expression induced formation of gH2AX
and 53BP1 foci and increased levels of chromatin-associated
gH2AX and 53BP1 (Figures 2C–2E). In contrast, myr-AKT1,
which did not induce BRCA1 chromatin dissociation, failed to
induce formation of gH2AX and 53BP1 foci or increase the levels
of chromatin-associated gH2AX and 53BP1 (Figures 2C–2E).
Consistently, it has been recently reported that cell senescence
induced by myr-AKT1 is not associated with SAHF formation or
the DNA damage response (Kennedy et al., 2011). Similarly,
PTEN knockdown induced expression ofmarkers of senescence
but had no effects on BRCA1 chromatin association and also
failed to trigger formation of gH2AX foci or SAHF (Figures
S2B–S2G). Likewise, it has been previously shown that senes-
cence induced by loss of PTEN is not associated with the accu-
mulation of DNA damage (Alimonti et al., 2010). The lack of both
DNA damage and BRCA1 chromatin dissociation in the PTEN
knockdown cells is consistent with the idea that BRCA1 chro-
matin dissociation contributes to DNA damage accumulation.1080 Developmental Cell 21, 1077–1091, December 13, 2011 ª2011We next directly measured the extent of DNA damage in
control, RAS, BRAF, and myr-AKT1-infected IMR90 cells using
the comet assay.Comparedwith controls, therewas a significant
increase in DNA damage in RAS and BRAF-infected IMR90
cells (p < 0.05), whereas the difference between control and
myr-AKT1-infected IMR90 cells was not significant (p > 0.05)
(Figures 2F and 2G). The combined data suggest that dissocia-
tion of BRCA1 from chromatin coincides with DNA damage
accumulation, correlates with SAHF formation, and is indepen-
dent of PI3K/AKT signaling.
BRCA1 Knockdown Induces Senescence
We next sought to test whether BRCA1 knockdown is sufficient
to drive SAHF formation and senescence in IMR90 cells. Toward
this goal, three individual short hairpin RNA to the human
BRCA1 (shBRCA1) genes with different degrees of BRCA1
knockdown efficacy were utilized. BRCA1 knockdown efficiency
was confirmed by IF staining and western blot (Figures 3A and
3B). Two individual shBRCA1s (#2 and #3), which efficiently
knocked downBRCA1, induced SAHF formation and expression
of SA-b-gal activity (Figures 3C–3F). Notably, an shBRCA1 (#1)
that knocked down BRCA1 with 40% efficacy at the total
protein level had no effect on SAHF formation or expression of
SA-b-gal activity (Figures 3A–3F). Interestingly, similar to the hy-
perproliferation observed in RAS-infected IMR90 cells prior to
cell cycle exit (e.g., Figures 1G and 1H; Figure S5) (Di Micco
et al., 2006), knockdown of BRCA1 in IMR90 cells also triggers
a minor but statistically significant hyperproliferation prior to
the cell cycle exit as demonstrated by increased BrdU incorpo-
ration (Figure S3A). Consistent with a previous report (Krum
et al., 2010), we observed an increase in expression of gH2AX
as well as formation of gH2AX foci following BRCA1 knockdown
(Figures S3B and S3C). We conclude that knockdown of BRCA1
is sufficient to drive senescence.
Downregulation of BRIP1 Expression Triggers BRCA1
Chromatin Dissociation
Next, we investigated the molecular mechanism underlying
BRCA1 chromatin dissociation. Notably, a fragment of the C
terminus of BRCA1 (aa 1314–1863) containing two BRCT
repeats was sufficient to be dissociated from chromatin in
IMR90 cells infected with RAS (Figure S4A), suggesting that
factors that interact with the BRCT repeats of BRCA1may trigger
BRCA1 chromatin dissociation.
BRCT repeats of BRCA1 bind to BRIP1, CtIP, and RAP80/
Abraxas (Wang et al., 2007; Yu et al., 1998, 2003). Compared
with controls, BRIP1 levels in both total cell lysates and the chro-
matin fractions of RAS-infected cells were dramatically
decreased (Figures 4A and 4B; Figure S4B). In contrast, expres-
sion levels of CtIP and RAP80 did not overtly change in RAS-in-
fected cells at the same time (Figure 4A). Notably, RAS-induced
downregulation of BRIP1 occurred prior to the cell cycle exit, as
reflected by the kinetics of cyclin A and pH3S10 expression (Fig-
ure 4B). Together, these results suggest that downregulation of
BRIP1 may trigger BRCA1 chromatin dissociation in RAS-in-
fected cells.
BRIP1 was first identified as a BRCA1 physiological
binding partner (Cantor et al., 2001). We next sought to deter-
mine whether BRIP1 is downregulated at the mRNA level inElsevier Inc.
Figure 2. Oncogene-Induced BRCA1 Chromatin Dissociation Correlates with DNA Damage Accumulation and SAHF Formation
(A) IMR90 cells were infected with control or the indicated activated oncogene-encoding retrovirus. Expression of BRCA1, histone H3, and b-actin in the
chromatin fractions and total cell lysates of indicated cells was assayed by western blot at day 4.
(B) Same as (A) but stained with DAPI and an antibody to mH2A, which is a component of SAHF. Percentage of SAHF-positive cells is indicated. Mean of three
independent experiments with SD. Arrows point to mH2A-stained inactivated X chromosome (Costanzi and Pehrson, 1998).
(C) Same as (A) but stained with DAPI or antibodies against gH2AX or 53BP1.
(D) Quantitation of (C). A total of 200 cells were examined for formation of gH2AX foci and 53BP1 foci. Cells with more than five nuclear foci for gH2AX or 53BP1
were counted as positive. Mean of three independent experiments with SD. *p < 0.05 and #p > 0.05 as compared to controls.
(E) Expression of gH2AX, 53BP1, and histone H3 in the chromatin fractions of IMR90 cells infected with vector control or indicated activated oncogenes as
determined by western blot.
(F) Same as (A). At day 2, drug-selected indicated cells were assayed for DNA damage by the comet assay. White bars indicate the examples of comet tails that
resulted from damaged DNA.
(G) Quantitation of (F). DNA damage from the comet assay is calculated as artificial Olive Moment unit as described in Experimental Procedures. The Olive
Moment in 100 cells from each group was measured. Mean of Olive Moment with SEM is shown in blue. *p < 0.05 and #p > 0.05 as compared to control.
See also Figure S2.
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mRNA in control and RAS-infected IMR90 cells was examined
by quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR). Compared with controls, BRIP1 mRNA levels were
significantly decreased as early as day 1 in RAS-infected cells
(Figure 4C). However, the BRCA1 mRNA expression level did
not statistically change at the same time (Figure 4C). This is
consistent with the idea that RAS-induced BRIP1 repression
triggers BRCA1 chromatin dissociation prior to RAS-induced
cell cycle exit.
We next sought to determine the mechanism underlying
BRIP1 downregulation in RAS-infected cells. BRIP1 mRNA
expression is downregulated in RAS-infected cells (Figure 4C),Developmentabut the stability of BRIP1 mRNA is not decreased by RAS
expression (data not shown), suggesting that BRIP1 may be
regulated at the transcriptional level. Consistently, the activity
of a 400 bp (300 bp – +100 bp) fragment of the proximal human
BRIP1 gene promoter was significantly suppressed in RAS-
infected cells (Figure S4C). Notably, deletion of a critical
B-Myb binding site from the BRIP1 promoter blocked the RAS-
mediated suppression of promoter activity, suggesting that
B-Myb plays a critical role in suppressing BRIP1 expression in
response to RAS (Figure S4C). Interestingly, it has previously
been demonstrated that B-Myb suppresses oncogenic RAS
induced senescence (Masselink et al., 2001). Consistently, we
observed downregulation of B-Myb in RAS-infected cells priorl Cell 21, 1077–1091, December 13, 2011 ª2011 Elsevier Inc. 1081
Figure 3. BRCA1 Knockdown Induces
Senescence
(A) IMR90 cells were infected with lentivirus en-
coding three individual shRNAs to the human
BRCA1 gene or a vector control and stained with
an anti-BRCA1 antibody. Note that the BRCA1
nuclear foci in control cells are associated with the
S/G2 phases of the cell cycle (Scully et al., 1997b),
indicating that the BRCA1 staining is specific.
(B) Same as (A) but assayed for BRCA1 and b-actin
expression by western blot. The levels of BRCA1
expression were quantified using the LI-COR
Odyssey imaging system (normalized using
b-actin as a loading control). Cont, control.
(C) Same as (A) but stained for SA-b-gal activity at
day 5.
(D) Quantitation of (C). A total of 100 cells were
examined for expression of SA-b-gal activity.
Mean of three independent experiments with SD.
*p < 0.03.
(E) Same as (C) but stained with DAPI to visualize
SAHF and an antibody against mH2A.
(F) Quantitation of (E). A total of 100 cells were
examined for SAHF and mH2A foci formation.
Mean of three independent experiments with SD.
*p < 0.02.
See also Figure S3.
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compared with controls (Figure S4D). Significantly, using an
anti-B-Myb antibody, chromatin immunoprecipitation studies
demonstrated that the binding of B-Myb to the promoter of the
human BRIP1 gene was significantly reduced in RAS-infected
cells compared with controls (Figure 4D). Additionally, it has
recently been demonstrated that B-Myb expression is sup-
pressed by upregulation of microRNA 29 (mir29) during senes-
cence (Lafferty-Whyte et al., 2009; Martinez et al., 2011). Consis-
tently, expression of mir29 was upregulated in RAS-infected
cells as early as 6 hr compared with controls (Figure S4E). We
conclude that RAS-mediated inhibition of B-Myb contributes to
the downregulation of BRIP1 during RAS-induced senescence.
Next, we asked whether knockdown of BRIP1 drives BRCA1
chromatin dissociation and senescence. Three individual
shRNAs to the human BRIP1 gene (shBRIP1) were developed,
and the efficacy of BRIP1 knockdown was confirmed by western
blot (Figure 4E). BRCA1 levels in the chromatin fractions of
shBRIP1-expressing cells were greatly reduced when compared
to controls (Figure 4E). In addition, we observed an increase in
expression of gH2AX in shBRIP1-expressing cells (Figure S4F).
Notably, BRIP1 knockdown induced expression of markers of
senescence, including SA-b-gal activity and SAHF formation
(Figures 4F and 4G). Consistent with this, BRIP1 knockdown1082 Developmental Cell 21, 1077–1091, December 13, 2011 ª2011 Elsevier Inc.increased levels of p16, p21, p53, and hy-
pophosphorylated pRB, demonstrating
activation of both the p53 and the pRB
pathways (Figure S4G). To limit off-target
effects, we sought to determine whether
BRIP1 restoration in shBRIP1-expressing
cells could prevent senescence induced
by BRIP1 knockdown. Indeed, ectopicexpression of an shBRIP1-resistant wild-type BRIP1 significantly
reduced the expression of markers of senescence induced by
shBRIP1 (Figures 4H–4J), indicating the specificity of the senes-
cence phenotype induced by BRIP1 knockdown. We conclude
that BRIP1 knockdown is sufficient to dissociate BRCA1 from
chromatin and induce senescence.
The interaction between BRIP1 and the BRCT repeats of
BRCA1 depends on phosphorylation of BRIP1 at serine 990
(S990) (Yu et al., 2003). Thus, we determined whether rescuing
of senescence by BRIP1 depends on the phosphorylation of
BRIP1 at S990. For this purpose, we made a serine to alanine
mutant (S990A) that mimics the nonphosphorylated state of
BRIP1 (Yu et al., 2003). Compared with wild-type BRIP1,
BRIP1 S990A failed to rescue the senescence induced by
BRIP1 knockdown (Figures 4H–4J). This result suggests that
the interaction between BRCA1 and BRIP1 plays a critical role
in regulating senescence.
Ectopic BRIP1 Rescues BRCA1 Chromatin Dissociation
and Suppresses RAS-Induced Senescence
We next asked whether ectopic BRIP1 might rescue BRCA1
chromatin dissociation and suppress oncogene-induced senes-
cence. Toward this goal, IMR90 cells were cotransduced with
a retrovirus encoding RAS to induce senescence and a retrovirus
Figure 4. BRIP1 Repression Triggers BRCA1 Chromatin Dissociation
(A) IMR90 cells were infected with control (Cont) or RAS-encoding retrovirus. Expression of BRIP1, BRCA1, RAP80, CtIP, and histone H3 in the chromatin
fractions of control and RAS-infected IMR90 cells was determined by western blot at the indicated time points.
(B) Same as (A). Expression of BRIP1, BRCA1, pH3S10, cyclin A, and b-actin was determined by western blot at the indicated time points in total cell lysates of
control and RAS-infected IMR90 cells.
(C) Same as (A). Expression of BRCA1 and BRIP1 mRNA was determined by qRT-PCR at indicated time points in control and RAS-infected IMR90 cells. Mean of
three independent experiments with SD. #p > 0.05 and *p < 0.01 versus controls.
(D) Same as (A). Control and RAS-infected cells were subjected to chromatin immunoprecipitation using an anti-B-Myb antibody as detailed in Experimental
Procedures. The immunoprecipitated DNA was subjected to quantitative PCR analysis using primers that cover the B-Myb binding site in the promoter of human
BRIP1 gene.
(E) IMR90 cells were infected with lentivirus-encoding shBRIP1 or control. Expression of BRIP1, BRCA1, histone H3, and b-actin in total cell lysates and in
chromatin fractions was determined by western blot.
(F) Same as (E) but stained for SA-b-gal activity or with DAPI to visualize SAHF.
(G) Quantitation of (F). Mean of four independent experiments with SEM. *p < 0.05.
(H) IMR90 cells were infected with a lentivirus-encoding shBRIP1 (#3) together with control, an shBRIP1-resistant wild-type BRIP1 (BRIP1 WT), or an shBRIP1-
resistant S990Amutant as detailed in the Experimental Procedures. Expression of BRIP1 and b-actin in drug-selected cells was determined by western blot (top).
In addition, expression of BRIP1 mRNA was determined by RT-PCR using primers designed to its 50 UTR region (only amplifies endogenous but not ectopic
BRIP1 mRNA) or its open reading frame (amplifies both endogenous and ectopic BRIP1 mRNA) (bottom).
(I) Same as (H) but stained for SA-b-gal activity or with DAPI to visualize SAHF.
(J) Quantitation of (I). Mean of three independent experiments with SD. *p < 0.05 and #p > 0.05 compared with only shBRIP1-expressing cells.
See also Figure S4.
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Figure 5. Ectopic BRIP1 Rescues BRCA1 Chromatin Dissociation and Suppresses Oncogene-Induced Senescence and DNA Damage
Response
(A) IMR90 cells were infected with retroviruses encoding RAS together with control (Cont), Myc-tagged wild type (WT) BRIP1, or BRIP1 S990A mutant. At day 4,
drug-selected cells were examined for expression of BRCA1, BRIP1, and histone H3 in the chromatin fractions and for expression of Myc-tagged ectopic BRIP1,
BRCA1, RAS, and b-actin in total cell lysates.
(B) Same as (A) but stained with antibodies against BRCA1 and cyclin A.
(C) Quantitation of (B). A total of 100 cyclin A-positive cells were examined for BRCA1 foci formation. Mean of three independent experiments with SD. *p < 0.05
and #p > 0.05 compared with RAS-infected controls.
(D) Same as (A) but stained for SA-b-gal activity or DAPI to visualize SAHF or an antibody against gH2AX to detect DNA damage.
(E) Quantitation of (D). Mean of four independent experiments with SD. *p < 0.015 and #p > 0.12 versus RAS-infected control cells.
(F) Same as (A) but equal numbers of cells (3 3 103 cells/well) were plated in 6-well plates in triplicate for focus formation assays. After 2 weeks in culture, the
plates were stained with 0.05% crystal violet in PBS to visualize foci. Shown are representative images of four independent experiments. Number of foci is
indicated as mean with SD.
(G) Same as (F), but the number of cells was counted at indicated time points. Mean of three independent experiments with SD.
(H) Control and the senescence-bypassed cells isolated from (G) were examined for RAS and b-actin expression by western blot.
See also Figure S5.
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BRCA1 Chromatin Dissociation Regulates Senescenceencoding a Myc-tagged wild-type BRIP1 or control. Compared
with controls, BRIP1 expression notably rescued the levels of
BRCA1 in thechromatin fractionsofRAS-infectedcells (Figure5A,
lane 2 versus lane 3). This was not due to a lower RAS expression
level because RAS was expressed at a higher level in ectopic1084 Developmental Cell 21, 1077–1091, December 13, 2011 ª2011BRIP1-expressing cells compared to controls (Figure 5A, lane 2
versus lane 3). In addition, the total BRCA1 protein level was
not increased by ectopic BRIP1 (Figure 5A, lane 2 versus lane
3), implying that the increased level of chromatin-associated
BRCA1 was not due to increased levels of total BRCA1.Elsevier Inc.
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BRCA1 Chromatin Dissociation Regulates SenescenceNotably, ectopic BRIP1 restored BRCA1 foci formation in
cyclin A-positive RAS-infected cells (Figures 5B and 5C). Inter-
estingly, ectopic BRIP1 did not affect RAS-induced hyperprolif-
eration (Figure S5), a trigger of the DNA damage response
(Di Micco et al., 2006), suggesting that ectopic BRIP1 may
instead affect DNA repair. In addition, expression of ectopic
BRIP1 in RAS-infected cells suppressed expression of markers
of senescence including SA-b-gal activity, SAHF formation,
and senescence-induced cell growth arrest, and inhibited
DNA damage response revealed by decreased gH2AX foci
formation when compared to controls (Figures 5D–5H). These
data further support the conclusion that BRIP1 plays a major
role in BRCA1 chromatin association during RAS-induced
senescence.
We next sought to determine whether suppression of BRCA1
chromatin dissociation by BRIP1 depends on the phosphoryla-
tion of BRIP1 at S990. Compared with wild-type BRIP1, the
BRIP1 S990A mutant failed to rescue BRCA1 chromatin dissoci-
ation in RAS-infected cells (Figure 5A, lane 3 versus lane 4) and
was also impaired in restoring BRCA1 foci in cyclin A-positive
RAS-infected cells (Figures 5B and 5C). These results imply
that the interaction between BRIP1 and BRCA1 is necessary
for suppression of BRCA1 chromatin dissociation by BRIP1.
Notably, the BRIP1 S990A mutant failed to suppress senes-
cence and its associated DNA damage accumulation in RAS-in-
fected IMR90 cells (Figures 5D–5G). We conclude that suppres-
sion of senescence by ectopic BRIP1 is dependent on its
interaction with BRCA1.
Oncogenic RAS Impairs the BRCA1-Mediated DNA
Repair Response prior to RAS-Induced Cell Cycle Exit
during Senescence
We next asked whether oncogene-induced BRCA1 chromatin
dissociation inactivates the BRCA1-mediated DNA repair
response. Upon DNA damage BRCA1 foci largely disappear in
normal cycling cells, although new damage-induced foci form
hours after DNA damage during the S/G2 phase of the cell cycle
(Chen et al., 1998; Durant and Nickoloff, 2005; Scully et al.,
1997a; Xu et al., 2001). To determine the effects of oncogenic
RAS expression on the BRCA1-mediated DNA repair response,
at day 2, control and RAS-infected IMR90 cells were treated with
2 Gy of IR to induce DNA DSBs. Notably, IR did not prevent
BRCA1 chromatin dissociation in RAS-infected cells (Figure 6A).
This was not due to a lack of DNA damage induction by IR in
RAS-infected cells because nearly 100% of both control and
RAS-infected cells were positive for gH2AX foci (Figure 6B).
We next examined formation of damage-induced BRCA1 foci
in the S/G2 phases of cycling cells by costaining cells with anti-
bodies against BRCA1 and cyclin A 5 hr after IR treatment (Peng
et al., 2006; Zhang et al., 2009). As expected, BRCA1 foci were
significantly induced upon IR treatment in controls (Figures 6C
and 6D). However, formation of damage-induced BRCA1 foci
was severely impaired in RAS-infected IMR90 cells when
exposed to IR (Figures 6C and 6D).
Functional BRCA1 is required for relocating/sustaining BRCA2
and its partner protein PALB2 at damage-induced foci (Sy et al.,
2009; Zhang et al., 2009), which are critical for BRCA1-mediated
DNA DSB repair (Huen et al., 2010). Consistently, formation of
damage-induced BRCA2 and PALB2 foci was also significantlyDevelopmentaimpaired in RAS-infected cells upon IR treatment compared to
controls (Figures 6E–6G). Based on these results, we conclude
that oncogenic RAS impairs the BRCA1-mediated DNA repair
response prior to the RAS-induced cell cycle exit during
senescence.
DNA Damage Promotes Senescence Bypass
in RAS-Infected Cells
The impaired ability of BRCA1 to repair DNA damage promotes
genomic instability, facilitates acquisition of oncogenic alter-
ations, and ultimately drives tumorigenesis (Turner et al., 2004).
Thus, we anticipated that impaired BRCA1-mediated DNA repair
might lead to DNA damage accumulation and allow for accumu-
lation of secondary hits that might promote senescence bypass.
Consistently, we reproducibly observed rare foci of senescence-
bypassed cells in RAS-infected IMR90 cells (Figure S6A). RAS
remains overexpressed in those cells (Figure S6B), suggesting
that senescence bypass is not due to loss of ectopic RAS
expression. To directly test our hypothesis, control and RAS-
infected IMR90 cells were treated with 2 Gy IR at day 2, and
the extent of DNA damage was measured by the comet assay.
At this time point, BRCA1 was largely dissociated from
chromatin in RAS-infected proliferative cells (Figure 1F). There
was increased DNA damage in IR-treated RAS-infected cells,
which was significantly greater than either IR-treated control
cells or RAS-infected cells without IR treatment (p < 0.05)
(Figures 7A and 7B). Notably, ectopic expression of wild-type
BRIP1, but not the BRIP1 S990A mutant, suppressed the DNA
damage accumulation in IR-treated RAS-infected cells (Figures
7C and 7D).
We next sought to determine whether this decreased ability
to repair DNA might lead to senescence bypass. We tested
this by focus formation and cell growth assays. Indeed, IR
treatment consistently induced senescence bypass as evi-
denced by both focus formation and apparent cell growth in
IR-treated cells compared to controls (Figures 7E and 7F).
Notably, senescence-bypassed cells formed colonies under
anchorage-independent growth condition in soft agar (Figures
7G and 7H). As a negative control, IR did not promote the
proliferation of control cells (Figure 7E; Figures S6D and S6E).
To eliminate the possibility that senescence bypass observed
in IR-treated cells was due to loss of ectopic RAS, these cells
were isolated and analyzed by western blot for exogenous RAS
expression. Compared with controls, RAS remained greatly
overexpressed in the senescence-bypassed cells (Figure 7I).
In addition, pRB was hyperphosphorylated, and p53 expres-
sion was reduced in the senescence-bypassed cells (Figure 7J),
suggesting that inactivation of the key senescence-promoting
pRB and p53 pathways contributes to the senescence bypass
induced by IR treatment. Notably, IR treatment has no effect on
senescence-associated cell growth arrest once RAS-infected
cells have exited from cell cycle (e.g., at day 7) (Figures S6C–
S6E). This result suggests that the senescence bypass
observed in IR-treated RAS-infected cells is not due to the
preexistence of senescence-resistant cells. Ectopic BRIP1
suppresses senescence (Figures 5D–5H), which prevented us
from determining whether rescuing BRCA1 chromatin dissocia-
tion by ectopic BRIP1 inhibits IR treatment-induced senes-
cence bypass in RAS-infected cells.l Cell 21, 1077–1091, December 13, 2011 ª2011 Elsevier Inc. 1085
Figure 6. BRCA1-Mediated DNA Repair Response Is Impaired prior to the Oncogene-Induced Cell Cycle Exit
(A) IMR90 cells were infected with control (C) or RAS (R)-encoding retrovirus. At day 2, drug-selected cells were treated with or without 2 Gy IR. After 5 hr of
recovery, expression of BRCA1, histone H3, and b-actin in total cell lysates and in the chromatin fractions was determined by western blot.
(B) Same as (A) but quantified for gH2AX foci formation in the indicated groups. Mean of three independent experiments with SD.
(C) Same as (A) but stained with antibodies against BRCA1 and cyclin A (using a rabbit anti-cyclin A antibody). Percentage of cyclin A-positive cells is indicated as
mean of three independent experiments with SD.
(D) Quantitation of (C). A total of 100 cyclin A-positive cells from each of the indicated groupswere examined for BRCA1 foci formation.Mean of three independent
experiments with SD.
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BRCA1 Chromatin Dissociation Regulates SenescenceIf senescence bypass in IR-treated cells is achieved through
accumulation of DNA damage and acquisition of secondary
hits due to BRCA1 chromatin dissociation induced by BRIP1
repression, we anticipated that BRIP1 might remain downregu-
lated, and BRCA1 might remain dissociated from chromatin
in the senescence-bypassed cells. Indeed, compared with
controls, BRIP1 remained downregulated, and BRCA1 remained
dissociated from chromatin in the senescence-bypassed cells
(Figure 7K). These results further support the idea that BRCA1
chromatin dissociation is not merely a consequence of senes-
cence-associated cell cycle exit because the senescence-
bypassed cells are highly proliferative. In addition, markers of
DNA damage (such as gH2AX and 53BP1 foci) were expressed
at higher levels in the senescence-bypassed cells compared to
controls (Figures 7L–7N). This is consistent with the idea that
BRCA1 chromatin dissociation contributes to DNA damage
accumulation in those cells. Together, these results suggest
that the loss of BRCA1-mediated DNA repair may also allow
for subsequent hits that ultimately enable a small fraction of
Ras-induced cells to bypass senescence.
DISCUSSION
Our study reveals that oncogenic RAS induces dissociation of
BRCA1 from chromatin prior to the cell cycle exit during RAS-
induced senescence. This dissociation of BRCA1 from chro-
matin coincides with DNA damage accumulation. Downregula-
tion of BRIP1, a BRCA1-binding partner, contributes to BRCA1
chromatin dissociation. Conversely, ectopic BRIP1 rescues
BRCA1 chromatin dissociation and suppresses RAS-induced
senescence. Significantly, the BRCA1-mediated DNA repair
response is impaired prior to the RAS-induced cell cycle exit,
which renders cells susceptible to the accumulation of
secondary hits. In some instances this may ultimately allow for
senescence bypass.
The Role of BRCA1 Chromatin Dissociation during
Oncogene-Induced Senescence
DNA damage persists in senescent cells (Rodier et al., 2009),
suggesting that defects in DNA repair may contribute to the
accumulation of DNA damage observed during senescence.
Our data reveal that BRCA1 chromatin dissociation coincides
with DNA damage accumulation, which occurs as early as the
hyperproliferation phase in RAS-infected cells (Figures 1F–1H,
1L, and 1M). A previous report by Di Micco et al. (2006) showed
that the accumulation of DNA damage closely follows the hyper-
proliferation phase in RAS-infected cells during senescence. The
basis for this minor discrepancy between these two reports
remains to be determined. It could be due to quantitative
approaches used in the current study, which make it easier to
reveal subtle differences at early stages (Figures 1L and 1M).
We showed that BRCA1 chromatin dissociation correlates with
the DNA damage response in both RAS and BRAF-infected cells(E) Same as (C) but stained with antibodies against BRCA1 and BRCA2.
(F) Same as (C) but stained with antibodies against BRCA1 and PALB2.
(G) Quantitation of results from (E) and (F). A total of 100 cells from each of the in
Mean of three independent experiments with SD. *p < 0.02 versus control IR-tre
Developmenta(Figure 2). Furthermore, BRCA1 knockdown in primary human
cells triggers the DNA damage response and induces senes-
cence (Figure 3; Figure S3B and S3C). Finally, suppression of
BRCA1 chromatin dissociation by ectopic BRIP1 suppresses
the DNA damage induced by oncogenic RAS (Figures 5B–5E).
Together, these results support the notion that BRCA1 chro-
matin dissociation contributes to the accumulation of DNA
damage during oncogene-induced senescence.
Herein, we demonstrated that RAS-induced dissociation of
BRCA1 from chromatin precedes SAHF formation (Figures 1C–
1F), and BRCA1 knockdown drives SAHF formation (Figure 3).
Furthermore, BRCA1 chromatin dissociation correlates with
SAHF formation in IMR90 cells expressing RAS and BRAF onco-
genes (Figures 2A and 2B). Consistent with this idea that BRCA1
antagonizes heterochromatin formation and/or maintenance, it
has been previously demonstrated that targeting BRCA1 to an
amplified lac operator-containing chromosome region in the
mammalian genome results in large-scale chromatin unfolding
(Ye et al., 2001). We were unable to ectopically express wild-
type BRCA1 in primary human cells (data not shown), which
prevented us from determining whether ectopically expressed
BRCA1 might suppress SAHF formation. However, ectopic
BRIP1 was able to rescue BRCA1 chromatin dissociation and
suppress SAHF formation (Figures 5D and 5E). Together, these
findings support the idea that BRCA1 chromatin dissociation
promotes senescence by contributing to SAHF formation.
Suppression of the DNA damage response by ectopic BRIP1
inhibits SAHF formation (Figures 5B–5E). Conversely, knock-
down of BRCA1, which induces DNA damage, drives SAHF
formation (Figure 3; Figure S3). In addition, AKT or shPTEN,
neither of which dissociates BRCA1 from chromatin, also fails
to induce a DNA damage response or SAHF formation (Figure 2;
Figure S2). Together, these data suggest that DNA damage
response triggered by BRCA1 chromatin dissociation is required
for SAHF formation. Indeed, there is evidence to suggest that
formation of SAHF limits the degree of DNA damage response
during oncogene-induced senescence (Di Micco et al., 2011).
However, the DNA damage response is not sufficient for SAHF
formation, which also requires activation of p16/pRB and
HIRA/PML pathways (Narita et al., 2003; Ye et al., 2007; Zhang
et al., 2005, 2007a). Overall, these results support the notion
that DNA damage is necessary but not sufficient for SAHF
formation.
The Role of BRIP1 Repression during
Oncogene-Induced Senescence
Stable BRIP1 knockdown reduces damage-induced BRCA1 foci
formation, and BRIP1-deficient cells demonstrate defects in the
number and intensity of BRCA1 foci (Peng et al., 2006). This
suggests that BRIP1 plays an important role in BRCA1-mediated
DNA repair. BRIP1 has been shown to be significantly downre-
gulated in response to RAS expression in primary human fibro-
blasts based on gene expression microarray analysis, whiledicated group were examined for BRCA1, BRCA2, and PALB2 foci formation.
ated cells. Cont, control.
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Figure 7. DNA Damage Promotes Senescence Bypass
(A) IMR90 cells were infected with control or RAS-encoding retrovirus, and drug-selected cells were treated with or without 2 Gy IR at day 2. After 5 hr of recovery,
comet assays were performed to detect DNA damage. Shown are representative images of six independent experiments. The white bar indicates an example of
the comet tails that reflect the extent of DNA damage. Note that a shorter exposure time was used here compared with Figure 2F to avoid saturation of comet tail
signal in IR-treated RAS-infected cells.
(B) Quantitation of results from (A). A total of 120 cells from each of the indicated groups were measured for Olive Moment. Means of Olive Moment with SEM are
indicated in blue. Note that there was a significant increase in DNA damage in RAS-infected cells without IR treatment compared with controls (p < 0.05).
(C) Same as (A). Comet assayswere performed to detect DNA damage in the indicated cells. Shown are representative images of three independent experiments.
Cont, control.
(D) Quantitation of results from (C). A total of 100 cells from each of the indicated groups were measured for Olive Moment. Means of Olive Moment with SEM are
indicated in blue.
(E) At day 2, control and RAS-infected BJ-hTERT cells were treated with or without 2 Gy IR. Equal numbers of the indicated cells (33 103 cells/well) were plated in
6-well plates for focus formation assays. After 2 weeks of culture, the plates were stained with 0.05% crystal violet in PBS to visualize foci. Shown are repre-
sentative images of four independent experiments. The number of foci is indicated as mean with SD.
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BRCA1 Chromatin Dissociation Regulates SenescenceCtIP and RAP80 are not among the list of genes whose expres-
sion is significantly changed in the same analysis (Mason et al.,
2004). Interestingly, BRIP1, but not CtIP or RAP80/Abraxas,
regulates DNA replication and is required for timely S phase
progression (Huen et al., 2010; Kumaraswamy and Shiekhattar,
2007), implying that the BRCA1/BRIP1 complex may regulate
senescence by altering DNA replication. In support of this idea,
RAS-induced senescence is characterized as a DNA damage
response triggered by aberrant DNA replication (Di Micco
et al., 2006). Furthermore, B-Myb, a key regulator of BRIP1
expression (Figure 4D; Figures S4C and S4D), is critical for
proper DNA replication and regulates the DNAdamage response
(Ahlbory et al., 2005; Lorvellec et al., 2010). Notably, BRIP1 is ex-
pressed at higher levels in advanced breast carcinomas, and its
overexpression correlates with a higher cell proliferation index
(Eelen et al., 2008), supporting the notion that high levels of
BRIP1may contribute to cell proliferation by suppressing senes-
cence (Figure 5). Taken together, these data imply a key role for
BRIP1 in accumulation of DNA damage during oncogene-
induced senescence.
The Role of BRCA1 Chromatin Dissociation in
Senescence Bypass
Oncogene-induced BRCA1 chromatin dissociation precedes
the cell cycle exit during senescence (Figure 1). Significantly,
oncogenic RAS impairs BRCA1-mediated DNA repair response
prior to the cell cycle exit during senescence (Figures 6 and 7).
This allows for the creation of a large time window for cells to
accumulate secondary oncogenic hits prior to the senescence-
associated cell cycle exit, which ultimately leads to senescence
bypass in a minority of cells while the vast majority of cells
eventually exit from the cell cycle and become senescent.
Consistent with this model, RAS-expressing cells accumulate
significantly greater DNA damage after IR treatment, and IR
treatment promotes senescence bypass in RAS-infected cells
(Figure 7). The mechanism we uncovered here may help explain
the paradox of why activation of oncogenes (such as RAS)
promotes senescence but at the same time predisposes cells
to transformation.
EXPERIMENTAL PROCEDURES
Chromatin Isolation and Chromatin Immunoprecipitation
Chromatin was prepared according to published methods (Me´ndez and
Stillman, 2000; Narita et al., 2006). Soluble proteins in supernatant 1 (SN1,
cytoplasmic) and 2 (SN2, nuclear) and chromatin-bound proteins in the chro-
matin fraction were detected by western blot.(F) Same as (E), but an equal number (13 104) of indicated cells were inoculated an
points. Mean of three independent experiments with SD.
(G) Equal numbers of parental and senescence-bypassed cells were grown under
colonies formed by the senescence-bypassed cells.
(H) Quantitation of (G). Mean of three independent experiments with SD.
(I) Expression of RAS and b-actin in control (C) and the senescence-bypassed (S
(J) Same as (I) but assayed for pRB, p53, and b-actin expression by western blo
(K) Same as (I) but examined for expression of BRIP1, BRCA1, and histone H3 in
(L) Same as (I) but stained with an anti-gH2AX antibody.
(M) Same as (L) but stained with an anti-53BP1 antibody. Arrows point to examp
(N) Quantitation of (L) and (M). A total of 100 cells from each indicated group we
experiments with SD.
See also Figure S6.
DevelopmentaChromatin immunoprecipitation in control and RAS-infected IMR90 cells
was performed at day 6 as previously described (Zhang et al., 2007b) using
a monoclonal anti-B-Myb antibody (Santa Cruz Biotechnology) or an iso-
type-matched IgG control. Immunoprecipitated DNA was analyzed using
SYBR Green quantitative PCR (SABiosciences) against the human BRIP1
gene promoter region containing the B-Myb binding site using the following
primers: forward, 50-ATAAAGCGGAGCCCTGGAAGAGAA-30; reverse, 50-
ATTCGTCTCGGGTTGTGTG-GTTGA-30.
Comet Assay
The comet assay was performed with the CometAssay (Trevigen) kit following
the manufacturer’s instructions. DNA damage was measured as the artificial
Olive Moment using CometScore software downloaded from http://www.
tritekcorp.com. To determine significance, the t test was performed using
GraphPad Prism software (http://www.graphpad.com).
Anchorage-Independent Growth in Soft Agar and Focus Formation
Assay
Anchorage-independent growth in soft agar was performed as previously
described (Li et al., 2010). For focus formation, 4 days after initial infection,
control or oncogenic H-RASG12V-encoding retrovirus-infected BJ-hTERT cells
were treated with 2 Gy IR. Cells were cultured for 6 days to eliminate the
apoptotic cells induced by IR. Then, control and H-RASG12V-expressing cells
with or without IR treatment were seeded into 6-well plates at a density of
3000 cells/well in triplicate. Two weeks later, the plates were stained with
0.05% crystal violet in PBS (Kuilman et al., 2008).
Retrovirus and Lentivirus Infections
Retrovirus production and transduction were performed as described previ-
ously (Ye et al., 2007; Zhang et al., 2005) using Phoenix cells to package the
infection viruses (Dr. Gary Nolan, Stanford University). Lentivirus was pack-
aged using the ViraPower Kit from Invitrogen following the manufacturer’s
instructions and as described previously (Li et al., 2010; Ye et al., 2007). Cells
infectedwith viruses encoding a drug-resistant gene to puromycin or neomycin
were selected in 1 and 500 mg/ml, respectively, of the corresponding agent.
Immunofluorescence, BrdU Labeling, FACS, and SA-b-gal Staining
Immunofluorescence staining and BrdU labeling for cultured cells were per-
formed as described previously using antibodies described above (Zhang
et al., 2005, 2007a, 2007b). Soluble protein pre-extraction with detergent
was carried out as described previously (Taddei et al., 2001). Briefly, cells
were incubated with PBS supplemented with 0.5% Triton X-100 for 5 min at
room temperature, followed by fixation in 4% paraformaldehyde (Sigma-
Aldrich) for 10 min. Fixed cells were incubated with a rabbit anti-BRCA1
antibody for 1 hr at room temperature and visualized by incubating the cells
with goat anti-rabbit Cy3 (Jackson ImmunoResearch; 1:5000) secondary
antibody followed by detection of BrdU using a FITC-labeled anti-BrdU anti-
body (BD Biosciences). FACS was performed as previously described (Ye
et al., 2007), and FlowJo software was used to analyze cell cycle distribution.
SA-b-gal staining was performed as previously described (Dimri et al., 1995).
For additional information about cell culture methods, RT-PCR, and lucif-
erase assays, as well as antibodies and plasmids used in this study, please
see the Supplemental Experimental Procedures.d cultured. The number of cells from each group was counted at indicated time
anchorage-independent conditions in soft agar. Arrow points to an example of
B) cells isolated from (F) was determined by western blot.
t.
total cell lysates and in the chromatin fractions by western blot.
les of 53BP1 foci-positive cells.
re examined for gH2AX and 53BP1 foci formation. Mean of three independent
l Cell 21, 1077–1091, December 13, 2011 ª2011 Elsevier Inc. 1089
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